Shares of Wright Medical ( WMGI) were among the worst-performing health-related stocks Wednesday, falling 21% after the maker of orthopedic devices warned that third-quarter results would fall below its previous guidance. The company now expects earnings of 10 cents to 11 cents a share on sales of about $73.4 million. Previously, Wright predicted it would earn between 16 cents and 18 cents a share on sales of $77.5 million to $79.5 million. Analysts surveyed by Thomson First Call had been expecting earnings of 17 cents a share on sales of $77.6 million. Looking ahead, Wright Medical now expects full-year earnings of 66 cents to 70 cents a share on sales of $315 million to $318 million. In July, the company projected that it would earn 85 cents to 88 cents a share on sales of $331 million to $335 million. "These newly revised targets incorporate the preliminary third-quarter results provided today and a fourth-quarter outlook reflecting reduced expectations for the company's domestic biologics product line and its Italian and French markets, modest acceleration of the company's domestic extremities product line growth rate and ongoing solid performances by the company's domestic reconstructive large joint business in line with recent industry rates of growth," the company said. Shares traded down $5.04 to $19.09. Shares of Human Genome Sciences ( HGSI) plummeted 35% after the biopharmaceutical company said its experimental lupus treatment didn't meet primary endpoints during a Phase II trial. Though LymphoStat-B was safe, well tolerated, and showed signs of clinical effect in patients with systemic lupus erythematosus, the drug failed to meet its primary endpoints of reducing the signs and symptoms of the disease at week 24 or increasing the time to the disease's flare-up to 52 weeks, the company said. Despite not meeting its endpoints, LymphoStat-B "reduced the signs and symptoms of SLE at week 52 at a level of statistical significance in seropositive patients," a subgroup that accounted for 75% of the study's patient population, the company said. Human Genome said it plans to move forward with Phase III development of the drug. Shares were down $4.86 to $9.11.